You see a filtered list - Keywords: Schaap-Selection
[1]K. Schubert, S. W. M. Olde Damink, M. von Bergen, F. G. Schaap,
"Interactions between bile salts, gut microbiota, and hepatic innate immunity", Immunological reviews, vol. 279, no. 1, 2017, pp. 23–35.
[bibtex] [url] [doi]
[2]P. B. Olthof, F. Huisman, F. G. Schaap, K. P. van Lienden, R. J. Bennink, R. F. van Golen, M. Heger, J. Verheij, P. L. Jansen, S. W. M. Olde Damink, T. M. van Gulik,
"Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model", British Journal of Surgery, vol. 104, no. 5, 2017, pp. 590–599.
[bibtex] [url] [doi]
[3]R. S. Kootte, E. Levin, J. Salojärvi, L. P. Smits, A. V. Hartstra, S. D. Udayappan, G. Hermes, K. E. Bouter, A. M. Koopen, J. J. Holst, F. K. Knop, E. E. Blaak, J. Zhao, H. Smidt, A. C. Harms, T. Hankemeijer, J. J. Bergman, H. A. Romijn, F. G. Schaap, S. W. M. Olde Damink, M. T. Ackermans, G. M. Dallinga-Thie, E. Zoetendal, W. M. de Vos, M. J. Serlie, E. S. Stroes, A. K. Groen, M. Nieuwdorp,
"Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition", Cell Metabolism, vol. 26, no. 4, 2017, pp. 611–619.e6.
[bibtex] [url] [doi]
[4]S. J. Zweers, A. Shiryaev, M. Komuta, M. Vesterhus, J. R. Hov, M. J. Perugorria, D. R. de Waart, J. Chang, S. Tol, A. A. te Velde, W. J. de Jonge, J. M. Banales, T. Roskams, U. Beuers, T. H. Karlsen, P. L. Jansen, F. G. Schaap,
"Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis", Liver International, vol. 36, no. 9, 2016, pp. 1370–1377.
[bibtex] [url] [doi]
[5]F. G. Schaap, M. Trauner and P. L. M. Jansen,
"Bile acid receptors as targets for drug development", Nature Reviews Gastroenterology & Hepatology, vol. 11, no. 1, 2013, pp. 55–67.
[bibtex] [url] [doi]
[6]F. D. M. van Schaik, R. M. Gadaleta, F. G. Schaap, S. W. C. van Mil, P. D. Siersema, B. Oldenburg, K. J. van Erpecum,
"Pharmacological Activation of the Bile Acid Nuclear Farnesoid X Receptor Is Feasible in Patients with Quiescent Crohn's Colitis", PLoS ONE, vol. 7, no. 11, 2012, pp. e49706.
[bibtex] [url] [doi]
[7]S. J. Zweers, K. A. Booij, M. Komuta, T. Roskams, D. J. Gouma, P. L. Jansen, F. G. Schaap,
"The human gallbladder secretes fibroblast growth factor 19 into bile: Towards defining the role of fibroblast growth factor 19 in the enterobiliary tract", Hepatology, vol. 55, no. 2, 2011, pp. 575–583.
[bibtex] [url] [doi]
[8]T. C. M. A. Schreuder, H. A. Marsman, M. Lenicek, J. R. van Werven, A. J. Nederveen, P. L. M. Jansen, F. G. Schaap,
"The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance", American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 298, no. 3, 2010, pp. G440–G445.
[bibtex] [url] [doi]
[9]F. G. Schaap, N. A. van der Gaag, D. J. Gouma, P. L. M. Jansen,
"High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis", Hepatology, vol. 49, no. 4, 2008, pp. 1228–1235.
[bibtex] [url] [doi]
[10]F. G. Schaap, P. C. N. Rensen, P. J. Voshol, C. Vrins, H. N. van der Vliet, R. A. F. M. Chamuleau, L. M. Havekes, A. K. Groen, K. W. van Dijk,
"ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis", Journal of Biological Chemistry, vol. 279, no. 27, 2004, pp. 27941–27947.
[bibtex] [url] [doi]